Metavia Inc (MTVA) Stock Price, Quote & News

Company Profile

MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. The company develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 702 9600

Website: www.metaviatx.com

Address:

545 Concord Avenue, Suite 210, Cambridge, United States

BULLISH1975 Jun. 12 at 6:04 PM

$ICU $SPCX $MTVA $GRI My 100 bagger pick in the next 2 years! If you have time do some DD or add to watch list!

0 · Reply

Kertzi Jun. 12 at 5:38 AM

$MTVA just presented at Emerging Growth Conference... 10 minutes. WHAT THEY SAID: — Mouse data. Again. Vanoglipel + Resmetirom combo lost 23.6% weight. In mice! — DA-1726 titration "going smoothly" — "Cash runway into Q4" — same line as last quarter — Zero shareholder questions answered WHAT THEY DIDN'T SAY: — FDA meeting for Vanoglipel: H1/26 deadline in 2 weeks. Total silence. — How they fund Phase 2/3, which requires hundreds of millions. Current cash: a few million. — Why vanoglipel is relevant when Rezdiffra is selling, semaglutide got MASH approval, and GLP-1/GIP/FGF21 combos from Big Pharma are already in trials! 8 employees. Going concern. $148M accumulated deficit. Reverse split approved up to 1:22. Next offering coming — you won't get advance notice, just a crash.

0 · Reply

AimHighnuwillhitsomewer Jun. 11 at 9:49 PM

$MTVA https://youtu.be/rb-xZV0wfxA?si=MayrWSvvXo1Z0Ydz

0 · Reply

AimHighnuwillhitsomewer Jun. 11 at 9:26 PM

$MTVA ?

0 · Reply

Nowhiteflag Jun. 11 at 6:16 PM

$MTVA Squeeze Probablity 74% Short interest is elevated Short interest: 12.13% of float With a float of only 3.37M shares, that’s enough to create sharp squeezes on any positive catalyst or even anticipation of one.

0 · Reply

Nowhiteflag Jun. 11 at 6:07 PM

$MTVA $20 Price Target Recent news flow has been very bullish The MarketWatch news feed shows a cluster of positive data releases over the last 2 weeks: “MetaVia highlights obesity and metabolic pipeline advancements” “MetaVia presents data at ADA supporting DA‑1726, vanoglipel” “MetaVia unveils promising Phase 1 data on DA‑1726” “Fein reiterates Buy… unchanged $20 price target”

0 · Reply

Nowhiteflag Jun. 11 at 3:54 PM

$MTVA Back to $3 soon. Then $9 by Sept 1st.

0 · Reply

Nowhiteflag Jun. 11 at 3:51 PM

$MTVA This is correct!

0 · Reply

Kertzi Jun. 10 at 4:11 AM

THE UGLY TRUTH BEHIND $MTVA Dong-A ST (Korea) controls this entire operation: — Sole IP owner/manufacturer — CEO is their former General Counsel — $316M in milestones payable to Dong-A ST if anything succeeds — Dong-A ST funds its R&D at zero risk. You fund it at 100% risk. NeuroBo. MetaVia. Different name. Same pipeline. Same Ponzi. → Niklosamide. Buried. → NB-01. Buried. → NB-02. Buried. → Gemcabene. Buried. → Vanoglipel: FDA meeting promised H1 2026. June 30 deadline... — 8 employees — Going concern warning — Cash gone Q4 2026 — Reverse split already approved (up to 1:22) — $148M accumulated deficit — CEO collecting $750K/year! And those pre-market pumps hitting $5.50 while U.S. investors sleep? Korean market hours. Every time... If it fails: you lose everything. If it succeeds: Dong-A ST collects $316M and owns the IPs. Big Pharma calls Seoul, not Cambridge. This isn't a biotech. It's a Nasdaq-listed fundraising vehicle for a Korean conglomerate's R&D budget.

1 · Reply

stockwitsuser2449 Jun. 9 at 9:05 PM

$MTVA has to account for drop before r/s

0 · Reply

MetaVia Transcript: Emerging Growth Conference 93

Jun 8, 2026, 10:00 AM EDT - 4 days ago

MetaVia Transcript: AGM 2026

2026-06-08T12:48:08.000Z - 4 days ago

MetaVia presents data at ADA supporting DA-1726, vanoglipel

Jun 8, 2026, 8:31 AM EDT - 4 days ago

MetaVia Presents New Late-Breaking Obesity and Metabolic Data at the ADA 2026 Scientific Sessions Supporting DA-1726 Differentiation and Vanoglipel Combination Potential

Jun 4, 2026, 8:31 AM EDT - 8 days ago

MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference

2026-05-27T13:33:47.000Z - 16 days ago

MetaVia’s DA-1726 shows efficacy in obesity and MASH presentations

May 27, 2026, 8:31 AM EDT - 16 days ago

MetaVia Presents Higher-Dose Phase 1 Results for DA-1726 at EASL Congress 2026, Supporting Potential in Obesity and MASH

2026-05-21T19:20:55.000Z - 22 days ago

3 Penny Stocks to Watch Now, 5/21/26

HCWB SLXN

May 20, 2026, 8:00 AM EDT - 23 days ago

MetaVia Highlights Peer-Reviewed Publication Supporting the Anti-Fibrotic Potential of Vanoglipel in MASH

May 18, 2026, 8:31 AM EDT - 25 days ago

MetaVia to Present Obesity Data at the American Diabetes Association's (ADA) 2026 Scientific Sessions

May 14, 2026, 4:05 PM EDT - 4 weeks ago

MetaVia Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 14, 2026, 4:00 PM EDT - 4 weeks ago

MetaVia Earnings release: Q1 2026

May 14, 2026, 4:00 PM EDT - 4 weeks ago

MetaVia Quarterly report: Q1 2026

May 14, 2026, 7:00 AM EDT - 4 weeks ago

MetaVia Slides: Investor presentation

May 11, 2026, 8:31 AM EDT - 4 weeks ago

MetaVia to Present Data Highlighting DA-1726, a GLP-1/Glucagon Dual Agonist, in a Late-Breaking Poster Presentation at the EASL Congress 2026

Apr 27, 2026, 8:00 AM EDT - 6 weeks ago

MetaVia Proxy statement: Proxy filing

Apr 15, 2026, 8:00 AM EDT - 2 months ago

MetaVia Proxy statement: Proxy filing

2026-04-10T12:36:24.000Z - 2 months ago

MetaVia says first patient dosed in Part 3 of Phase 1 trial of DA-1726

Apr 10, 2026, 8:30 AM EDT - 2 months ago

MetaVia Doses the First Patient in Higher-Dose Phase 1 Study of DA-1726, Its GLP-1 and Glucagon Dual Agonist for the Treatment of Obesity

2026-03-26T12:43:01.000Z - 2 months ago

MetaVia: Cash position adequate to fund operations into 4Q26

2026-03-26T12:41:30.000Z - 2 months ago

MetaVia CEO says ‘significant progress advancing our cardiometabolic portfolio’

Mar 26, 2026, 8:31 AM EDT - 2 months ago

MetaVia Reports Year End 2025 Financial Results and Provides Corporate Update

Mar 26, 2026, 8:30 AM EDT - 2 months ago

MetaVia Annual report: Q4 2025

Mar 26, 2026, 8:30 AM EDT - 2 months ago

MetaVia Earnings release: Q4 2025

Mar 26, 2026, 7:00 AM EDT - 2 months ago

MetaVia Slides: Investor presentation

2026-03-18T12:05:12.000Z - 3 months ago

MetaVia announces IRB at Clinical Pharmacology of Miami approved Phase 1 study

Mar 18, 2026, 8:00 AM EDT - 3 months ago

MetaVia Advances GLP-1-Based Obesity Program with IRB Approval for Higher-Dose Phase 1 Studies of DA-1726, a GLP-1 and Glucagon Dual Agonist Demonstrating Best-in-Class Potential for Weight Loss and Glucose Control

Mar 12, 2026, 10:30 AM EDT - 3 months ago

MetaVia Transcript: Life Sciences Virtual Investor Forum

2026-03-12T13:09:03.000Z - 3 months ago

MetaVia expands global patent protection for vanoglipel into 2035

Mar 12, 2026, 9:01 AM EDT - 3 months ago

MetaVia Expands Global Patent Protection for Vanoglipel, Supporting Metabolic and Liver Disease Therapy Through 2035

Mar 4, 2026, 8:31 AM EST - 3 months ago

MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum

Feb 25, 2026, 10:15 AM EST - 3 months ago

MetaVia Transcript: Emerging Growth Virtual Conference

Feb 13, 2026, 8:31 AM EST - 4 months ago

MetaVia Builds Comprehensive Global Patent Protection for DA-1726, Securing Exclusive Rights to Novel Obesity and Metabolic Therapy Through 2041

Feb 4, 2026, 8:00 AM EST - 4 months ago

MetaVia Announces Positive AI-Modeling Results from its Ongoing Syntekabio Collaboration, Confirming Key Therapeutic Targets for Vanoglipel

Jan 16, 2026, 4:01 PM EST - 5 months ago

MetaVia Announces the Closing of $9.3 Million Underwritten Public Offering, Including Full Exercise of Allotment Option

Jan 15, 2026, 9:32 AM EST - 5 months ago

MetaVia Announces the Pricing of $8.1 Million Underwritten Public Offering

Jan 12, 2026, 7:00 AM EST - 5 months ago

MetaVia Registration statement: Registration Filing

Jan 5, 2026, 8:30 AM EST - 5 months ago

MetaVia Reports Positive Statistically Significant Results from Its Phase 1b Clinical Trial of DA-1726 In Metabolic Disease - Demonstrating Strong Glycemic Response, Significant Direct Hepatic Effects, Robust Weight Loss and Favorable Safety Profile

Jan 5, 2026, 7:00 AM EST - 5 months ago

MetaVia Registration statement: Registration Filing

Dec 29, 2025, 8:31 AM EST - 5 months ago

MetaVia to Participate in and Sponsor the 10th Annual MASH-TAG 2026 Conference

Dec 22, 2025, 8:31 AM EST - 6 months ago

MetaVia Regains Compliance with Nasdaq Minimum Bid Price Requirement

Dec 2, 2025, 8:45 AM EST - 6 months ago

MetaVia Inc. Announces 1-for-11 Reverse Stock Split

Nov 7, 2025, 8:31 AM EST - 7 months ago

MetaVia Presents Positive New Phase 2a Data on Vanoglipel (DA-1241) in Patients with Presumed MASH at the AASLD The Liver Meeting® 2025

Nov 6, 2025, 8:31 AM EST - 7 months ago

MetaVia Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 6, 2025, 8:30 AM EST - 7 months ago

MetaVia Quarterly report: Q3 2025

Nov 6, 2025, 8:30 AM EST - 7 months ago

MetaVia Earnings release: Q3 2025

Nov 4, 2025, 4:01 PM EST - 7 months ago

MetaVia to Present New Phase 1 and Pre-Clinical Data on DA-1726 at ObesityWeek® 2025

Oct 27, 2025, 8:31 AM EDT - 8 months ago

MetaVia Announces Poster Presentation on Vanoglipel (DA-1241) at the AASLD Liver Meeting

Oct 20, 2025, 8:31 AM EDT - 8 months ago

MetaVia Announces Poster Presentations on DA-1726 at ObesityWeek® 2025

Oct 14, 2025, 8:31 AM EDT - 8 months ago

MetaVia to Present at the H.C. Wainwright Liver Disease Virtual Conference

Sep 5, 2025, 7:00 AM EDT - 10 months ago

MetaVia Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Aug 26, 2025, 8:31 AM EDT - 10 months ago

MetaVia to Present at Upcoming Investor and Industry Conferences

Aug 7, 2025, 8:31 AM EDT - 11 months ago

MetaVia Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 7, 2025, 8:30 AM EDT - 11 months ago

MetaVia Quarterly report: Q2 2025

Aug 7, 2025, 8:30 AM EDT - 11 months ago

MetaVia Earnings release: Q2 2025

Aug 6, 2025, 8:31 AM EDT - 11 months ago

MetaVia Extends 48 mg MAD Portion of Its Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity to 8 Weeks and Announces Fifth Weekly Dose in First Patient

Aug 4, 2025, 8:31 AM EDT - 11 months ago

MetaVia Announces AI-Driven Collaboration with Syntekabio to Explore Additional Indications for DA-1241

Jul 9, 2025, 8:31 AM EDT - 1 year ago

MetaVia Doses First Patient in the 48 mg MAD Cohort of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity to Further Explore Maximum Tolerated Dose

Jul 2, 2025, 8:00 AM EDT - 1 year ago

MetaVia Registration statement: Registration Filing

Jun 21, 2025, 9:00 AM EDT - 1 year ago

MetaVia Presents Pre-Clinical Data on DA-1241 Demonstrating Additive Hepatoprotective Effects in Combination With Efruxifermin at the ADA's 85th Scientific Session

Jun 12, 2025, 1:00 PM EDT - 1 year ago

MetaVia Transcript: Life Sciences Investor Forum

Jun 10, 2025, 8:31 AM EDT - 1 year ago

MetaVia to Present at the Life Sciences Virtual Investor Forum June 12th

Jun 10, 2025, 8:00 AM EDT - 1 year ago

MetaVia Proxy statement: Proxy Filing

Jun 4, 2025, 8:31 AM EDT - 1 year ago

MetaVia Announces Poster Presentation on DA-1241 at the ADA's 85th Scientific Sessions

May 27, 2025, 8:00 AM EDT - 1 year ago

MetaVia Proxy statement: Proxy Filing

May 21, 2025, 4:25 PM EDT - 1 year ago

MetaVia Transcript: Emerging Growth Conference 82

May 21, 2025, 7:00 AM EDT - 1 year ago

MetaVia Slides: Investor Presentation

May 14, 2025, 4:05 PM EDT - 1 year ago

MetaVia Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025, 12:00 AM EDT - 1 year ago

MetaVia Quarterly report: Q1 2025

May 14, 2025, 12:00 AM EDT - 1 year ago

MetaVia Earnings release: Q1 2025

May 9, 2025, 8:01 AM EDT - 1 year ago

MetaVia Announces $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules

May 7, 2025, 2:00 AM EDT - 1 year ago

MetaVia Presents Data on DA-1241, a GPR119 Agonist, Demonstrating Both Hepatoprotective and Glucose-Regulating Effects in Patients with Presumed MASH, at the EASL Congress 2025

Apr 23, 2025, 8:31 AM EDT - 1 year ago

MetaVia Announces Late-Breaking Poster Presentation on DA-1241 at the EASL Congress 2025

Apr 22, 2025, 8:31 AM EDT - 1 year ago

MetaVia Reports Additional Positive Top-Line Results From the MAD Part 2 of Its Phase 1 Study of DA-1726, a Novel 3:1 Ratio GLP-1 and Glucagon Dual Receptor Agonist to Treat Obesity, Further Demonstrating Its Best-In-Class Potential

Apr 15, 2025, 7:01 AM EDT - 1 year ago

MetaVia Announces Positive Top-Line Data From the 4-Week Phase 1 MAD Trial of DA-1726, a Novel 3:1 Ratio GLP-1 Glucagon Dual Receptor Agonist to Treat Obesity, Showing Compelling Weight Loss and Safety Effects With Potential Best-In-Class Glucose Control (GLP-1R), Waist Reduction (GCGR), and Tolerability

Apr 15, 2025, 7:00 AM EDT - 1 year ago

MetaVia Slides: Investor Presentation

Mar 20, 2025, 7:31 AM EDT - 1 year ago

MetaVia Reports Year End 2024 Financial Results and Provides Corporate Update

Mar 20, 2025, 7:30 AM EDT - 1 year ago

MetaVia Annual report: Q4 2024

Mar 20, 2025, 7:30 AM EDT - 1 year ago

MetaVia Earnings release: Q4 2024

Jan 10, 2025, 8:05 AM EST - 1 year ago

MetaVia to Hold Advisory Committee Meeting at the 9th Annual MASH-TAG 2025 Conference

Jan 9, 2025, 7:00 AM EST - 1 year ago

MetaVia Slides: Study Result

Dec 2, 2024, 7:00 AM EST - 1 year ago

MetaVia Slides: Investor Presentation

Nov 18, 2024, 8:01 AM EST - 1 year ago

NeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaVia - Reflecting the Company's Focus on Cardiometabolic Diseases

Nov 13, 2024, 8:01 AM EST - 1 year ago

NeuroBo Pharmaceuticals to Participate in Investor Conferences in November

Nov 7, 2024, 8:01 AM EST - 1 year ago

NeuroBo Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 7, 2024, 7:00 AM EST - 1 year ago

MetaVia Quarterly report: Q3 2024

Nov 7, 2024, 7:00 AM EST - 1 year ago

MetaVia Earnings release: Q3 2024

Nov 4, 2024, 8:01 AM EST - 1 year ago

NeuroBo Pharmaceuticals Completes Last Patient Last Visit in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

Oct 1, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals to Participate in Investor Conferences in October

Sep 30, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Announces Positive Top-Line Data From the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

Sep 3, 2024, 8:01 AM EDT - 1 year ago

NeuroBo to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Aug 21, 2024, 8:00 AM EDT - 1 year ago

MetaVia Proxy statement: Proxy Filing

Aug 14, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Update

BULLISH1975 Jun. 12 at 6:04 PM

$ICU $SPCX $MTVA $GRI My 100 bagger pick in the next 2 years! If you have time do some DD or add to watch list!

0 · Reply

Kertzi Jun. 12 at 5:38 AM

0 · Reply

AimHighnuwillhitsomewer Jun. 11 at 9:49 PM

$MTVA https://youtu.be/rb-xZV0wfxA?si=MayrWSvvXo1Z0Ydz

0 · Reply

AimHighnuwillhitsomewer Jun. 11 at 9:26 PM

$MTVA ?

0 · Reply

Nowhiteflag Jun. 11 at 6:16 PM

0 · Reply

Nowhiteflag Jun. 11 at 6:07 PM

0 · Reply

Nowhiteflag Jun. 11 at 3:54 PM

$MTVA Back to $3 soon. Then $9 by Sept 1st.

0 · Reply

Nowhiteflag Jun. 11 at 3:51 PM

$MTVA This is correct!

0 · Reply

Kertzi Jun. 10 at 4:11 AM

1 · Reply

stockwitsuser2449 Jun. 9 at 9:05 PM

$MTVA has to account for drop before r/s

0 · Reply

gilsoo Jun. 9 at 3:52 PM

$MTVA Jari Keränen, it's ironic how MetaVia is viewed through completely different lenses depending on where you look. In Korea, some investors see MetaVia as a burden on Dong-A ST because of the ongoing R&D spending. In the U.S., some investors dismiss MetaVia as merely a Dong-A affiliate with little independent value. Both narratives miss the bigger picture. What matters is the technology and the data. The ADA presentation highlighted the potential of DA-1241, and if that leads to a licensing deal, strategic partnership, or even an acquisition, it would be a positive outcome for both the company and its shareholders. At the end of the day, value is created by successful science and business execution, not by the labels people attach to the company.

2 · Reply

Kertzi Jun. 9 at 3:43 PM

$MTVA PAID PUMPER ON THE MOVE. @gilsoo Let's fact-check this point by point. All from the 10-K — public SEC filing, go read it yourself. "Not Dong-A ST's branch" Sole manufacturer: Dong-A ST. All IP: Dong-A ST. CEO: former General Counsel of Dong-A ST. Milestone obligations to Dong-A ST: $316M. You tell me what that looks like? "Would remain listed on Nasdaq" It remains listed because of reverse splits, not business value. They already have the next R/S approved (up to 1:22). That's not a sign of health. That's a survival mechanism. "Big Pharma acquisition would be positive" If Big Pharma wants DA-1726, they call Seoul. The IP is in Korea. Acquiring MetaVia means buying $316M in milestone obligations on top of the asset. Why would they do that? "Focus on pipeline rights value" MetaVia holds a license, not IPs. One question for you: when did the CEO last buy shares on the open market? Once again - check the SEC filings.

0 · Reply

gilsoo Jun. 9 at 2:43 PM

$MTVA I believe the shareholder approval for the reverse stock split is a necessary measure to meet Nasdaq's listing requirements and proactively prevent delisting. While some may view this negatively due to potential dilution or future equity offerings, I see it as a much better alternative than the alternative—delisting. Given the promising results of the DA-1241 combination therapy, I hope we see positive news on a licensing deal before the reverse split occurs, and that the split ratio is kept to a minimum.

1 · Reply

Kertzi Jun. 9 at 1:34 PM

$MTVA

2 · Reply

gilsoo Jun. 9 at 12:06 PM

$MTVA As investors, the reverse stock split is certainly important and deserves attention. However, I believe investors should also focus on the DA-1241 combination data that was selected as a Late-Breaking Abstract and presented at the ADA 2026 meeting. The data showed results that are strong enough to attract serious attention, in my opinion. If these findings generate interest from larger pharmaceutical companies and lead to potential collaboration opportunities, MetaVia's valuation could be significantly higher than where it is today. The market currently seems focused on financing concerns, while paying very little attention to the scientific value and business development potential of DA-1241. Just my opinion. Do your own research.

0 · Reply

Joefreeagent Jun. 9 at 11:29 AM

$MTVA Scam

0 · Reply

gilsoo Jun. 9 at 10:27 AM

$MTVA DA-1241 was featured in ADA 2026 Late-Breaking Abstract presentations. The most interesting data came from the DA-1241 + Resmetirom (first approved MASH therapy) combination study. • Resmetirom alone → No significant weight loss • DA-1241 + Resmetirom → 23.6% body weight reduction • Fat mass ↓ 43.5% • ALT ↓ 83.5% • Significant improvements in liver inflammation and fibrosis biomarkers Despite these results, investors seem focused on financing concerns and the reverse split rather than the scientific value of the pipeline. Why was Resmetirom chosen as the combination partner? Maybe it's purely scientific. But it's also possible that there is a broader business development strategy behind this choice. In my opinion, these ADA results demonstrate meaningful combination potential and are strong enough to attract attention from larger pharmaceutical companies. At the current valuation, the market appears to be assigning very little value to DA-1241's combination opportunity. Just my opinion.

1 · Reply

Kertzi Jun. 9 at 4:43 AM

$MTVA The real question is: why was the R/S approved even though the stock has recently traded as high as $5.50? Answer: They are going to issue 10 million+ new shares into the market, and this upcoming dilution will push the share price back down to a penny stock club.

0 · Reply

Kertzi Jun. 9 at 2:48 AM

$MTVA MetaVia Shareholders Approve Equity Plan and Reverse Split MetaVia Inc. shareholders officially approved the equity plan amendment and a reverse stock split at the Annual Meeting. The equity plan adds 200,000 shares, while the reverse split authorizes the Board of Directors to enact a ratio between 1-for-5 and 1-for-22 to maintain Nasdaq listing compliance.

0 · Reply

Nowhiteflag Jun. 8 at 9:57 PM

$MTVA Back to $3 by EOW.

0 · Reply

eagermnk Jun. 8 at 9:26 PM

$MTVA garbage

0 · Reply

Spaiss888 Jun. 8 at 8:36 PM

$MTVA down 30% lol, for what? Obviously a big 💩 that I shouldn’t have gotten into and now I’m out. Good luck everyone.

1 · Reply

Market Cap	10.12M
Revenue (ttm)	0.00
Net Income (ttm)	-12.97M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	590,300
Avg Vol	4,602,146
Day's Range	N/A - N/A
Shares Out	5.16M
Stochastic %K	25%
Beta	0.92
Analysts	Strong Sell
Price Target	$19.33